Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022

doi:10.19401/j.cnki.1007-3639.2023.03.001

Abstract

Abstract:

Renal cell carcinoma (RCC) is one of the three major urinary system tumors. With the changes of lifestyle and the rise of obesity, hypertension and other diseases, the incidence of RCC is increasing. The onset of RCC is hidden, and RCC has strong heterogeneity. Most RCC patients are found accidentally by imaging examination, so many patients were diagnosed in the advanced stage. Although the emergence of targeted therapy and immunotherapy has greatly prolonged the survival time of patients with advanced RCC, due to many pathological types of RCC, it is still difficult for many patients to benefit from the systematic treatment. Many basic and clinical studies are devoted to the development of new targets or drugs to prolong the survival time of patients. This article reviewed the advances in the research, diagnosis and treatment of RCC in 2022.

Key words: Renal cell carcinoma, Immunotherapy, Targeted therapy, Basic research, Clinical research

CLC Number:

R737.11

TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022[J]. China Oncology, 2023, 33(3): 191-200.

References 67

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105. doi: S0302-2838(16)00206-2 pmid: 26935559
[3]	THORSTENSON A, BERGMAN M, SCHERMAN-PLOGELL A H, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register[J]. Scand J Urol, 2014, 48(3): 231-238. doi: 10.3109/21681805.2013.864698 pmid: 24666102
[4]	BUKAVINA L, BENSALAH K, BRAY F, et al. Epidemiology of renal cell carcinoma: 2022 update[J]. Eur Urol, 2022, 82(5): 529-542. doi: 10.1016/j.eururo.2022.08.019 pmid: 36100483
[5]	ROGER V L, GO A S, LLOYD-JONES D M, et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association[J]. Circulation, 2011, 123(4): e18-e209.
[6]	LIU X Q, PEVERI G, BOSETTI C, et al. Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2019, 142: 86-93. doi: S1040-8428(19)30163-5 pmid: 31387065
[7]	EHDAIE B, FURBERG H, ZABOR E C, et al. Comprehensive assessment of the impact of cigarette smoking on survival of clear cell kidney cancer[J]. J Urol, 2014, 191(3): 597-602. doi: 10.1016/j.juro.2013.08.081 pmid: 24018238
[8]	BHASKARAN K, DOUGLAS I, FORBES H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults[J]. Lancet, 2014, 384(9945): 755-765. doi: 10.1016/S0140-6736(14)60892-8
[9]	CHOI Y, PARK B, JEONG B C, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis[J]. Int J Cancer, 2013, 132(3): 625-634. doi: 10.1002/ijc.27639 pmid: 22610826
[10]	KAELIN W G JR. The VHL tumor suppressor gene: insights into oxygen sensing and cancer[J]. Trans Am Clin Climatol Assoc, 2017, 128: 298-307. pmid: 28790514
[11]	AL-BAYATI O, HASAN A, PRUTHI D, et al. Systematic review of modifiable risk factors for kidney cancer[J]. Urol Oncol, 2019, 37(6): 359-371. doi: 10.1016/j.urolonc.2018.12.008
[12]	HIDAYAT K, DU X, ZOU S Y, et al. Blood pressure and kidney cancer risk: meta-analysis of prospective studies[J]. J Hypertens, 2017, 35(7): 1333-1344. doi: 10.1097/HJH.0000000000001286 pmid: 28157813
[13]	LEE J E, HUNTER D J, SPIEGELMAN D, et al. Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies[J]. J Natl Cancer Inst, 2007, 99(10): 801-810. doi: 10.1093/jnci/djk181 pmid: 17505075
[14]	BAGNARDI V, ROTA M, BOTTERI E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis[J]. Br J Cancer, 2015, 112(3): 580-593. doi: 10.1038/bjc.2014.579
[15]	QU Y Y, FENG J W, WU X H, et al. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population[J]. Nat Commun, 2022, 13(1): 2052. doi: 10.1038/s41467-022-29577-x pmid: 35440542
[16]	LI Y, LIH T M, DHANASEKARAN S M, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness[J]. Cancer Cell, 2023, 41(1): 139-163.e17. doi: 10.1016/j.ccell.2022.12.001 pmid: 36563681
[17]	LI R Y, FERDINAND J R, LOUDON K W, et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer[J]. Cancer Cell, 2022, 40(12): 1583-1599.e10. doi: 10.1016/j.ccell.2022.11.001 pmid: 36423636
[18]	BÜTTNER F A, WINTER S, STÜHLER V, et al. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy[J]. Genome Med, 2022, 14(1): 105. doi: 10.1186/s13073-022-01105-y pmid: 36109798
[19]	PATEL S A, HIROSUE S, RODRIGUES P, et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer[J]. Nature, 2022, 606(7916): 999-1006. doi: 10.1038/s41586-022-04809-8
[20]	ZHOU J, SIMON J M, LIAO C, et al. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma[J]. Mol Cell, 2022, 82(16): 3030-3044. e8. doi: 10.1016/j.molcel.2022.06.003 pmid: 35764091
[21]	XIE Y C, SAHIN M, SINHA S, et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes[J]. Nat Cancer, 2022, 3(2): 188-202. doi: 10.1038/s43018-021-00316-3
[22]	BOOTSMA M, MCKAY R R, EMAMEKHOO H, et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma[J]. J Clin Oncol, 2022, 40(31): 3633-3641. doi: 10.1200/JCO.22.00219
[23]	HAGIWARA M, FUSHIMI A, MATSUMOTO K, et al. The significance of PARP1 as a biomarker for predicting the response to PD-L1 blockade in patients with PBRM1-mutated clear cell renal cell carcinoma[J]. Eur Urol, 2022, 81(2): 145-148. doi: 10.1016/j.eururo.2021.09.024
[24]	GOLKARAM M, KUO F S, GUPTA S, et al. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape[J]. Genome Med, 2022, 14(1): 143. doi: 10.1186/s13073-022-01146-3 pmid: 36536472
[25]	QU Y Y, WU X H, ANWAIER A, et al. Proteogenomic characterization of MiT family translocation renal cell carcinoma[J]. Nat Commun, 2022, 13(1): 7494. doi: 10.1038/s41467-022-34460-w pmid: 36470859
[26]	WANG Q, ZHANG Y, ZHANG B L, et al. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma[J]. Nat Commun, 2022, 13(1): 31. doi: 10.1038/s41467-021-27660-3 pmid: 35013217
[27]	GE X, LI M D, YIN J X, et al. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma[J]. Mol Cell, 2022, 82(7): 1249-1260.e7. doi: 10.1016/j.molcel.2022.01.029 pmid: 35216667
[28]	SUN R, BREAU R H, MALLICK R, et al. Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian kidney cancer information system[J]. Can Urol Assoc J, 2021, 15(4): 132-137.
[29]	VASUDEV N S, WILSON M, STEWART G D, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer[J]. BMJ Open, 2020, 10(5): e035938.
[30]	VOGEL C, ZIEGELMÜLLER B, LJUNGBERG B, et al. Imaging in suspected renal-cell carcinoma: systematic review[J]. Clin Genitourin Cancer, 2019, 17(2): e345-e355. doi: 10.1016/j.clgc.2018.07.024
[31]	ROSSI S H, PREZZI D, KELLY-MORLAND C, et al. Imaging for the diagnosis and response assessment of renal tumours[J]. World J Urol, 2018, 36(12): 1927-1942. doi: 10.1007/s00345-018-2342-3 pmid: 29948048
[32]	MA H, SHEN G H, LIU B, et al. Diagnostic performance of ¹⁸F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis[J]. Nucl Med Commun, 2017, 38(2): 156-163. doi: 10.1097/MNM.0000000000000618
[33]	VOSS J, DRAKE T, MATTHEWS H, et al. Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort[J]. BJU Int, 2020, 125(4): 561-567. doi: 10.1111/bju.15001 pmid: 31955483
[34]	KOTECHA R R, FLIPPOT R, NORTMAN T, et al. Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma[J]. J Natl Compr Canc Netw, 2021, 19(4): 432-438. doi: 10.6004/jnccn.2020.7634
[35]	SILVERMAN S G, PEDROSA I, ELLIS J H, et al. Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment[J]. Radiology, 2019, 292(2): 475-488. doi: 10.1148/radiol.2019182646 pmid: 31210616
[36]	CHANDRASEKAR T, AHMAD A E, FADAAK K, et al. Natural history of complex renal cysts: clinical evidence supporting active surveillance[J]. J Urol, 2018, 199(3): 633-640. doi: S0022-5347(17)77564-7 pmid: 28941915
[37]	LJUNGBERG B, ALBIGES L, ABU-GHANEM Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update[J]. Eur Urol, 2022, 82(4): 399-410. doi: 10.1016/j.eururo.2022.03.006 pmid: 35346519
[38]	LEVERIDGE M J, FINELLI A, KACHURA J R, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy[J]. Eur Urol, 2011, 60(3): 578-584. doi: 10.1016/j.eururo.2011.06.021 pmid: 21704449
[39]	MOCH H, AMIN M B, BERNEY D M, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2022, 82(5): 458-468. doi: 10.1016/j.eururo.2022.06.016 pmid: 35853783
[40]	JIA L, CARLO M I, KHAN H, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases[J]. Mod Pathol, 2019, 32(9): 1329-1343. doi: 10.1038/s41379-019-0273-1
[41]	COLOMBO P, SMITH S C, MASSA S, et al. Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait[J]. Urol Case Rep, 2015, 3(6): 215-218. doi: 10.1016/j.eucr.2015.07.011 pmid: 26793557
[42]	YU L, LI J, XU S P, et al. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report[J]. Diagn Pathol, 2016, 11(1): 98. pmid: 27733182
[43]	KRYVENKO O N. Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution[J]. Urol Oncol, 2017, 35(6): 454-455. doi: 10.1016/j.urolonc.2017.03.023
[44]	SUKOV W R, HODGE J C, LOHSE C M, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients[J]. Mod Pathol, 2012, 25(11): 1516-1525. doi: 10.1038/modpathol.2012.107
[45]	TAO J J, WEI G, PATEL R, et al. ALK fusions in renal cell carcinoma: response to entrectinib[J]. JCO Precis Oncol, 2018, 2: 1-8. doi: 10.1200/PO.18.00185 pmid: 35135161
[46]	SHAH R B, STOHR B A, TU Z J, et al. Renal cell carcinoma with leiomyomatous stroma harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity[J]. Am J Surg Pathol, 2020, 44(5): 571-581. doi: 10.1097/PAS.0000000000001422
[47]	SMITH S C, SIROHI D, OHE C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma[J]. Histopathology, 2017, 71(1): 42-52. doi: 10.1111/his.13183 pmid: 28165631
[48]	WYVEKENS N, VALTCHEVA N, MISCHO A, et al. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach[J]. Genes Chromosom Cancer, 2020, 59(11): 611-619. doi: 10.1002/gcc.v59.11
[49]	PALSGROVE D N, LI Y J, PRATILAS C A, et al. Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum[J]. Am J Surg Pathol, 2018, 42(9): 1166-1181. doi: 10.1097/PAS.0000000000001111 pmid: 29975249
[50]	TRPKOV K, ABOU-OUF H, HES O, et al. Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity[J]. Am J Surg Pathol, 2017, 41(10): 1299-1308. doi: 10.1097/PAS.0000000000000838 pmid: 28786877
[51]	MACLENNAN S, IMAMURA M, LAPITAN M C, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer[J]. Eur Urol, 2012, 61(5): 972-993. doi: 10.1016/j.eururo.2012.02.039 pmid: 22405593
[52]	CAPITANIO U, TERRONE C, ANTONELLI A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T_1a-T_1b renal mass and normal preoperative renal function[J]. Eur Urol, 2015, 67(4): 683-689. doi: 10.1016/j.eururo.2014.09.027
[53]	ALAM R, PATEL H D, OSUMAH T, et al. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study[J]. BJU Int, 2019, 123(1): 42-50. doi: 10.1111/bju.14490 pmid: 30019484
[54]	SPRENKLE P C, POWER N, GHONEIM T, et al. Comparison of open and minimally invasive partial nephrectomy for renal tumors 4-7 centimeters[J]. Eur Urol, 2012, 61(3): 593-599. doi: 10.1016/j.eururo.2011.11.040 pmid: 22154728
[55]	BAKOUNY Z, EL ZARIF T, DUDANI S, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium[J]. Eur Urol, 2023, 83(2): 145-151. doi: 10.1016/j.eururo.2022.10.004
[56]	MOTZER R, ALEKSEEV B, RHA S Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma[J]. N Engl J Med, 2021, 384(14): 1289-1300. doi: 10.1056/NEJMoa2035716
[57]	RINI B I, PLIMACK E R, STUS V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2019, 380(12): 1116-1127. doi: 10.1056/NEJMoa1816714
[58]	CHOUEIRI T K, POWLES T, BUROTTO M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med, 2021, 384(9): 829-841. doi: 10.1056/NEJMoa2026982
[59]	CHOUEIRI T K, POWLES T B, ALBIGES L, et al. LBA8-phase Ⅲ study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)[J]. Ann Oncol, 2022, 33(suppl_7): S808-S869.
[60]	JONASCH E, MICHAEL BAUER T, PAPADOPOULOS K P, et al. Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up[J]. J Clin Oncol, 2022, 40(suppl 16): Abstr 4509.
[61]	MCDERMOTT D F, CHOUEIRI T K, TYKODI S, et al. 1453P-phase Ⅱ study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): update from cohort 2 of LITESPARK-003[J]. Ann Oncol, 2022, 33(suppl_7): S660-S680.
[62]	DIZMAN N, MEZA L, BERGEROT P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial[J]. Nat Med, 2022, 28(4): 704-712. doi: 10.1038/s41591-022-01694-6 pmid: 35228755
[63]	DIAB A, GOGAS H J, SANDHU S K, et al. 785O-PIVOT IO 001: first disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)[J]. Ann Oncol, 2022, 33 (suppl_7): S356-S409.
[64]	ARMSTRONG A J, HALABI S, EISEN T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17(3): 378-388. doi: S1470-2045(15)00515-X pmid: 26794930
[65]	PAL S K, TANGEN C, THOMPSON I M JR, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet, 2021, 397(10275): 695-703. doi: 10.1016/S0140-6736(21)00152-5 pmid: 33592176
[66]	LEE C H, VOSS M H, CARLO M I, et al. Phase Ⅱ trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates[J]. J Clin Oncol, 2022, 40(21): 2333-2341. doi: 10.1200/JCO.21.01944
[67]	LEE C H, SHAH A Y, RASCO D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111/KEYNOTE-146): a phase 1b/2 study[J]. Lancet Oncol, 2021, 22(7): 946-958. doi: 10.1016/S1470-2045(21)00241-2